New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: Performance characteristics

Journal of Analytical Toxicology

Volumn 24, Issue 8, 2000, Pages 726-732

  Schwenzer, K S ^a   Pearlman, R ^a   Tsilimidos, M ^a   Salamone, S J ^a   Cannon, R C ^b   Wong, S H Y ^b   Gock, S B ^b   Jentzen, J J ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; PERFORMANCE;

EID: 0034468832     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/24.8.726     Document Type: Article

References (12)

1. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: Two techniques evaluated and modified for improved performance
2. Plasma and urine concentrations of flunitrazepam by immunoassay and GC/MS after a single oral dose
3. Flunitrazepam excretion pattern using the Abuscreen On Trak and OnLine immunoassays: Comparison with GC-MS
4. Detection of benzodiazepines in serum or plasma on the COBAS® INTEGRA
5. Benzodiazepine assay for the COBAS® INTEGRA
6. Urine concentrations of benzodiazepines, including flunitrazepam, after a single oral dose, using the cassette COBAS® INTEGRA serum benzodiazepines assay
7. Analysis of barbiturates in serum or plasma on the COBAS® INTEGRA
8. Comparison of the serum barbiturate fluorescence polarization immunoassay by the COBAS INTEGRA to a GC/MS method
9. Serum barbiturates assay on the COBAS® INTEGRA
10. A sensitive GC-MS procedure for the analysis of fiunitrazepam and its metabolites in urine
11. Certainty in toxicology screening, in-service training and continuing education